Cybin Highlights 12-Month Efficacy Results From CYB003 Psilocin Program And DMT Drug-Drug Interaction Study At ACNP Annual Meeting

BenzingaDec 10 20:59

Cybin Announces Poster Presentations at the 2024 American College of Neuropsychopharmacology Annual Meeting, Including CYB003 12-Month Efficacy Results

BusinesswireDec 10 20:30

Facet Life Sciences Named Regulatory Partner for Cybin's Neuropsychiatry Therapeutics Development Pipeline

PR NewswireDec 5 03:00

Cybin to Discuss Breakthrough Treatments at Fireside Chat

TipRanksDec 4 21:09

Cybin to Participate in Water Tower Research Fireside Chat on December 11, 2024

BusinesswireDec 4 20:30

Cybin Inc. Advances in Mental Health Treatments

TipRanksNov 26 11:58